Most investments in genomics and other life science information companies didn't work. Tool companies--those that sell instruments for discovery research--can make successful investments, but they require a clear agreement up-front on the exit strategy: acquisition.
Q: Most investments in genomics and other life science information companies didn't work. What about tool companies--those that sell instruments to pharmaceutical and biotech companies to help with discovery research or clinical development?
A: On its face, investing in life science instrumentation companies is a sound strategy. Instrument companies share a number of the favorable attributes associated with investments in medical device companies:...
Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
But the French major is still keen on early-stage M&A.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Buy boosts the French major's immunology pipeline.
Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.
